228.3 ð©º å §ç§å°ç§èåç
228.3.0.1 1ïžâ£ Babesia vs Malaria Differential
| Feature | Babesia | Malaria |
|---|---|---|
| Geography | USA NE/Midwest, Europe | Tropical worldwide |
| Vector | Tick | Mosquito |
| Liver stage | No | Yes |
| Multiple rings in 1 RBC | Common | Uncommon |
| Pigment (hemozoin) | None | Yes |
| Gametocytes | None | Yes |
| Maltese cross | Pathognomonic | Absent |
| Severity | Asplenic + immunocompromise | All non-immune |
228.3.0.2 2ïžâ£ Asplenic Patient with Tick Exposure
- Highest risk
- Pre-immunization counseling + tick avoidance
- Suspicious febrile illness â immediate workup
- Lower threshold for hospitalization + treatment
- Exchange transfusion readiness
228.3.0.3 3ïžâ£ Exchange Transfusion Indications
- Parasitemia > 10%
- Severe hemolysis (Hb < 7)
- AKI
- Refractory to antibiotic
- Multi-organ involvement
- Asplenic + high parasitemia
- ICU setting; rapid reduction of parasitemia
228.3.0.4 4ïžâ£ Babesia in Pregnancy
- Acquisition + vertical transmission
- Severe disease + obstetric complications
- Quinine 3rd trimester avoided (PROM, abortion risk)
- Alternative: clindamycin + atovaquone-proguanil
228.3.0.5 5ïžâ£ Immunocompromise Babesia Management
- Longer treatment (6+ wk minimum)
- Combination therapy more aggressive
- Monitor PCR for clearance
- B-cell depletion (rituximab) â recurrence common, may need maintenance
- Transplant recipients: reduce immunosuppression cautiously
228.3.0.6 6ïžâ£ Transfusion Transmission
- USA NE NIH/FDA priority
- Donor screening expanded 2024
- Recipients in non-endemic areas can acquire
- Hospital surveillance
228.3.0.7 7ïžâ£ å¥ä¿ / Taiwan
- çœèŠ endemic; mostly imported
- éå ± mandatory
- å¥ä¿ atovaquone + azithro + clindamycin + quinine for confirmed
- Tick-borne disease awareness
228.3.0.8 8ïžâ£ Recent Babesia Research
- B. duncani severity reports increasing
- Climate change â Ixodes range expansion
- New diagnostic + therapeutic targets
- Vaccine research